PDE4A and COVID-19: In accordance, PDE4 inhibitors, such as Apremilast, when administered actively for the treatment of COVID-19 or passively as a targeted therapy of underlying diseases, displayed rapid and positive effects in a subgroup of severe SARS-CoV-2 pneumonia [158,159,160].